7028 Dasatinib and docetaxel combination treatment for patients with metastatic castration-resistant prostate cancer (CRPC): analysis of Study CA180-086

J.Araujo; P.Mathew; A.J.Armstrong; E.L.Braud; E.Posadas; M.Lonberg; G.Gallick; G.C.Trudel; P.Paliwal; C.J.Logothetis

首页> 外文期刊>European Journal of Cancer Supplements >7028 Dasatinib and docetaxel combination treatment for patients with metastatic castration-resistant prostate cancer (CRPC): analysis of Study CA180-086

【24h】

7028 Dasatinib and docetaxel combination treatment for patients with metastatic castration-resistant prostate cancer (CRPC): analysis of Study CA180-086

机译：7028达沙替尼联合多西他赛治疗转移性去势抵抗性前列腺癌（CRPC）的患者：研究CA180-086的分析

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2009年第2期|共1页
作者
J.Araujo; P.Mathew; A.J.Armstrong; E.L.Braud; E.Posadas; M.Lonberg; G.Gallick; G.C.Trudel; P.Paliwal; C.J.Logothetis;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel [J] . John C Araujo, Geralyn C Trudel, Prashni Paliwal Cancer Management and Research . 2013,第2016期

机译：接受达沙替尼联合多西他赛治疗的转移性去势抵抗性前列腺癌患者长期使用达沙替尼
2. 7004 Final results of a randomized phase II study of OGX-011 (OGX) in combination with docetaxel (DOC)/prednisone versus docetaxel/prednisone in patients with metastatic castration resistant prostate cancer (CRPC) [J] . K.N.Chi, S.J.Hotte, E.Yu, European Journal of Cancer Supplements . 2009,第2期

机译：7004 OGX-011（OGX）联合多西他赛（DOC）/泼尼松与多西他赛/泼尼松对转移性去势抵抗性前列腺癌（CRPC）患者的随机II期研究的最终结果
3. A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial [J] . van Dodewaard-de Jong Joyce M., de Klerk John M. H., Bloemendal Haiko J., European Journal of Nuclear Medicine and Molecular Imaging . 2017,第8期

机译：对重复的铼-188-HEDP的随机的II类研究与多西紫杉醇和泼尼松与多西紫杉醇和泼尼松相结合，仅在抗阉割的前列腺癌（CRPC）转移到骨中; 税款II审判
4. Metastatic Hormone-Sensitive and Castration-Resistant Prostate Cancer: A Decade of Progress and Ongoing Discoveries [C] . Leonel Hernez-Aya, Maha Hussain Genitourinary Cancers Symposium. . 2014

机译：转移激素敏感和阉割的前列腺癌：进步和持续发现的十年
5. Muscle Cross-Sectional Area Is Improved and Physical Funciton Is Maintained After Home-Based Exercise in Men with Metastatic Castration-Resistant Prostate Cancer Undergoing Androgen Deprivation Therapy [D] . Alzer, Mohamdod Saber. 2020

机译：改善肌横截面积，并且在具有转移阉割的前列腺癌接受雄激素剥夺治疗的男性中的男性锻炼之后，将物理静脉凝集维持
6. Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel [O] . John C Araujo, Geralyn C Trudel, Prashni Paliwal 2013

机译：接受达沙替尼联合多西他赛治疗后长期使用达沙替尼治疗转移性去势抵抗性前列腺癌患者
7. Risk factors for metastatic castration-resistant prostate cancer (CRPC) predict long-term treatment with docetaxel. [O] . Takashi Kawahara, Yasuhide Miyoshi, Zenkichi Sekiguchi, 2012

机译：转移性去势抵抗性前列腺癌（CRpC）的危险因素预测多西紫杉醇的长期治疗。

7028 Dasatinib and docetaxel combination treatment for patients with metastatic castration-resistant prostate cancer (CRPC): analysis of Study CA180-086

著录项

相似文献

相关主题

期刊订阅